Hepatotoxicity of Rifampicin and Pyrazinamide Treatment Excluding Isoniazid |
Choi, Ik Su
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Park, I-Nae (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Hong, Sang-Bum (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Oh, Yeon-Mok (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Lim, Chae-Man (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Lee, Sang Do (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Koh, Younsuck (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Kim, Woo Sung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Kim, Dong Soon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Kim, Won Dong (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) Shim, Tae Sun (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center) |
1 | Korean National Institute of Health. Guidelines for the control of tuberculosis. Seoul: Korean National Institute of Health; 2005 |
2 | Centers for Disease Control and Prevention, American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9 |
3 | Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-50 DOI ScienceOn |
4 | Korean Food and Drug Administration. Guideline for the treatment of latent tuberculosis infection in patients treated with TNF blockers. Seoul: Korean Food and Drug Administration; 2004 |
5 | Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7 DOI ScienceOn |
6 | Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-5 |
7 | Bandyopadhyay T, Murray H, Metersky ML. Costeffectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest 2002; 121:1771-5 DOI |
8 | Medinger A. Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. Chest 2002;121:1710-2 DOI |
9 | Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-7 DOI ScienceOn |
10 | Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7 DOI ScienceOn |
11 | Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-51 DOI ScienceOn |
12 | American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51 |
13 | McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003;123:102-6 DOI |
14 | Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkin SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62 DOI ScienceOn |
15 | Choi IS, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, et al. Hepatotoxicity of rifampicin and pyrazinamide combination treatment: treatment with rifampicin and pyrazinamide containing regimen excluding isoniazid due to isoniazid resistance. Tuberc Respir Dis 2004;57(Suppl 2):52 |
16 | Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002;51:998-9 |
17 | Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002;288:165-6 DOI ScienceOn |